Join the Department of Oncology for Dr. Maria MacDonald's presentation "Belzutifan, Selective Inhibitor of HIF-2alpha; Targeted Therapy for Renal Cell Carcinoma and other tumors in von Hippel Lindau Disease," hosted by Dr. Stephen Welch, Division of Medical Oncology.

Dr. MacDonald's presentation will explore:

the pathophysiology of von Hippel Lindau disease
the mechanism of Belzutifan, selective HIF-2alpha inhibitor and the results of a recently published phase two trial published in the New England Journal of Medicine, November 2021
A clinical case which illustrates drug access to Belzutifan and a proposed Oncology Care pathway for eligible patients

This event will be held virtually using WebEx. Please visit our Oncology Grand Rounds event page for more information about this event.

URL:

https://bit.ly/3BNdAyg

Contact:

Kimberly Scott - Coordinator, Centre for Translational Cancer Research (CTCR)
Kimberly.Scott@lhsc.on.ca

Event Type:

Lecture / Seminar

Audience:

Faculty, Graduate Students, Professional Students, Postdocs

Department:

Brain and Mind Institute, Department of Oncology, Schulich School of Medicine & Dentistry